Skip to main content

Table 2 Patient demographics and clinical characteristics at therapy initiation (2004–2015)

From: Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry

Characteristic

TNFi monotherapy

Other biologic monotherapya

csDMARD monotherapy

TNFi + csDMARD combination therapy

Other biologica + csDMARD combination therapy

Overall

 

N = 770

N = 369

N = 2982

N = 3022

N = 884

N = 8027

Female, n (%)

615 (79.9)

299 (81.0)

2264 (75.9)

2330 (77.1)

703 (79.5)

6211 (77.4)

Age (years), mean (SD)

53.6 (12.6)

58.9 (14.1)

58.1 (13.4)

56.0 (12.7)

57.8 (13.0)

56.9 (13.1)

Race, White, n (%)

635 (82.5)

311 (84.3)

2472 (82.9)

2460 (81.4)

731 (82.7)

6609 (82.3)

RA duration (years), mean (SD)

8.8 (9.5)

11.5 (10.1)

6.0 (8.4)

8.4 (9.1)

10.6 (9.8)

7.9 (9.2)

Number of previous therapies used, mean (SD)

 csDMARDs

1.2 (1.1)

1.5 (1.1)

0.9 (0.9)

1.5 (0.9)

1.8 (1.0)

ND

 Biologics

0.8 (1.0)

1.6 (1.3)

0.2 (0.6)

0.7 (0.9)

1.6 (1.3)

ND

Previous csDMARD use, n (%)

 Naïve

224 (29.1)

76 (20.6)

1922 (64.5)

1748 (57.8)

459 (51.9)

4429 (55.2)

 Experienced

546 (70.9)

293 (79.4)

1060 (35.5)

1274 (42.2)

425 (48.1)

3598 (44.8)

CDAI, mean (SD)

21.4 (14.7)

25.3 (14.7)

16.8 (12.9)

20.8 (14.8)

24.5 (14.5)

20.0 (14.4)

CDAI categories, n (%)

 Remission

72 (9.6)

15 (4.2)

310 (10.7)

224 (7.6)

28 (3.2)

649 (8.3)

 Low

112 (14.9)

36 (10.0)

753 (25.9)

582 (19.7)

103 (11.8)

1586 (20.2)

 Moderate

246 (32.7)

115 (31.9)

1017 (35.0)

976 (33.0)

308 (35.2)

2662 (33.9)

 High

322 (42.8)

195 (54.0)

826 (28.4)

1178 (39.8)

437 (49.9)

2958 (37.7)

PGA, mean (SD)

38.1 (24.2)

42.6 (23.8)

28.8 (21.9)

35.5 (23.7)

41.2 (22.7)

34.2 (23.4)

mHAQ, mean (SD)

0.5 (0.5)

0.6 (0.6)

0.4 (0.5)

0.5 (0.5)

0.6 (0.5)

0.5 (0.5)

Comorbidities, n (%)

 Cardiovascular

58 (7.5)

42 (11.4)

246 (8.2)

250 (8.3)

110 (12.4)

706 (8.8)

 Malignancy

30 (3.9)

35 (9.5)

228 (7.6)

150 (5.0)

68 (7.7)

511 (6.4)

 Serious infectionb

29 (3.8)

38 (10.3)

138 (4.6)

130 (4.3)

90 (10.2)

425 (5.3)

 Diabetes

57 (7.4)

33 (8.9)

269 (9.0)

247 (8.2)

101 (11.4)

707 (8.8)

  1. N = total number of patients in each cohort; n = number of patients with baseline demographic or clinical characteristic
  2. anon-TNFi and tsDMARDs
  3. bNot captured before 2008
  4. CDAI clinical disease activity index, csDMARD conventional synthetic disease-modifying antirheumatic drug, mHAQ modified health assessment questionnaire, ND not determined, PGA physician global assessment, RA rheumatoid arthritis, SD standard deviation, TNFi tumor necrosis factor inhibitor, tsDMARD targeted synthetic disease-modifying antirheumatic drug
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us